AUL
DGX icon

AlphaGrep UK Ltd’s Quest Diagnostics DGX Stock Holding History

AlphaGrep UK Ltd’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$413K Buy
2,106
+705
+50% +$137K 0.12% 345
2025
Q4 		$243K Buy
+1,401
New +$255K 0.08% 542

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

AlphaGrep UK Ltd's DGX Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its Quest Diagnostics (DGX) stake by 50% in Q1 2026, buying an estimated $137K and bringing the position to 2,106 shares worth $413K. The position accounts for 0.12% of the portfolio, ranked #345.

AlphaGrep UK Ltd first reported a position in DGX in Q4 2025 and has held it in 2 quarters since. 1,067 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • AlphaGrep UK Ltd held 2,106 shares of Quest Diagnostics worth $413K as of Q1 2026.
  • AlphaGrep UK Ltd bought 705 Quest Diagnostics shares in Q1 2026, an estimated $137K.
  • Quest Diagnostics made up 0.12% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #345 holding.
  • AlphaGrep UK Ltd first reported a position in Quest Diagnostics in Q4 2025 and has held it in 2 quarters since.
  • 1,067 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.